Latest Pharma Insights
Herbalife Approaching Executive Suite Shift While Pivoting To Personalization Focus
Nutrition, health and wellness product direct seller says CEO Stephan Gratziani will leave on Oct. 31 while continuing as a strategy and business development consultant and CFO John DeSimone will serve as interim CEO before retiring at the end of the year.
HBW Insight - August 31, 2026
Nutrition, health and wellness product direct seller says CEO Stephan Gratziani will leave on Oct. 31 while continuing as a strategy and business development consultant and CFO John DeSimone will serve as interim CEO before retiring at the end of the year.
HBW Insight - August 31, 2026
Global Regulators Align on Cosmetics E-Labeling
Cosmetic regulators from across the globe came together and agreed on general principles for minimizing barriers to trade at the meeting of the International Cooperation on Cosmetics Regulation this summer.
HBW Insight - August 31, 2026
Cosmetic regulators from across the globe came together and agreed on general principles for minimizing barriers to trade at the meeting of the International Cooperation on Cosmetics Regulation this summer.
HBW Insight - August 31, 2026
Boston Scientific Discontinues Imager II Catheter. FDA Issues Early Alert Over Detachment Risk
The FDA said Boston Scientific is removing its Imager II Angiographic Catheters because a manufacturing issue could cause the catheter tip to degrade and detach during use. The company has also decided to discontinue the device. Two serious injuries and no deaths are associated with the recall.
Medtech Insight - August 31, 2026
The FDA said Boston Scientific is removing its Imager II Angiographic Catheters because a manufacturing issue could cause the catheter tip to degrade and detach during use. The company has also decided to discontinue the device. Two serious injuries and no deaths are associated with the recall.
Medtech Insight - August 31, 2026
Lilly To Pay Up To $2.9bn For Merida Biosciences And Its Antibody-Degrading Autoimmune Platform
Lilly inks its 13th acquisition of 2026 with a deal for Merida Biosciences and its Phase I antibody-degrader.
Scrip - August 31, 2026
Lilly inks its 13th acquisition of 2026 with a deal for Merida Biosciences and its Phase I antibody-degrader.
Scrip - August 31, 2026
Warburg Pincus-Backed Integrace Builds Out Senior Leadership Bench
Integrace, which was acquired by Warburg Pincus in July, assembles senior leadership team to anchor India pharma platform push. Industry veteran Bhaskar Iyer and senior executives from MSD and Roche Diagnostics come on board.
Scrip - August 31, 2026
Integrace, which was acquired by Warburg Pincus in July, assembles senior leadership team to anchor India pharma platform push. Industry veteran Bhaskar Iyer and senior executives from MSD and Roche Diagnostics come on board.
Scrip - August 31, 2026
Pipeline Watch: Eight Approvals And One Phase III Readout
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Scrip - August 31, 2026
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Scrip - August 31, 2026
Philips Joins ARPA-H’s Autonomous Stroke Intervention Race With $33.7m Award
ARPA-H is funding four competing teams to solve the same problem — too few stroke specialists, too far from too many patients — and Philips' $33.7m award is the latest piece of a $175m bet on autonomous endovascular robotics.
Medtech Insight - August 31, 2026
ARPA-H is funding four competing teams to solve the same problem — too few stroke specialists, too far from too many patients — and Philips' $33.7m award is the latest piece of a $175m bet on autonomous endovascular robotics.
Medtech Insight - August 31, 2026
MHRA Directs NHS To Review Cobalt-Chrome Modular-Neck Hip Implants From Five Makers
The UK regulator's review of cobalt-chrome dual-taper modular-neck hip systems from manufacturers like Stryker and Smith+Nephew found heightened wear, corrosion and tissue-reaction risks in about 750 patients. All affected implants had already been withdrawn from the market.
Medtech Insight - August 31, 2026
The UK regulator's review of cobalt-chrome dual-taper modular-neck hip systems from manufacturers like Stryker and Smith+Nephew found heightened wear, corrosion and tissue-reaction risks in about 750 patients. All affected implants had already been withdrawn from the market.
Medtech Insight - August 31, 2026
NSCLC Expansion Win In China Trial For Tagrisso/Orpathys Combo
The clear clinical benefit of the first-line c-Met inhibitor Orpathys and EGFR inhibitor Tagrisso combo could reshape primary treatment strategy for locally advanced or metastatic EGFR-mutated NSCLC with MET overexpression.
Scrip - August 31, 2026
The clear clinical benefit of the first-line c-Met inhibitor Orpathys and EGFR inhibitor Tagrisso combo could reshape primary treatment strategy for locally advanced or metastatic EGFR-mutated NSCLC with MET overexpression.
Scrip - August 31, 2026
ESC: Wainua Data From AstraZeneca/Ionis Undercut ATTR-CM Combo Case
The fine print of a failed trial in transthyretin-mediated amyloid cardiomyopathy muddies the waters on the idea that “silencers” and older “stabilizer” therapies work better together.
Scrip - August 31, 2026
The fine print of a failed trial in transthyretin-mediated amyloid cardiomyopathy muddies the waters on the idea that “silencers” and older “stabilizer” therapies work better together.
Scrip - August 31, 2026
FDA Consumer Health Advisory: Further OTC Regulatory Reform Needed
What's happening, why it matters and what's next at FDA. This edition explores the ongoing changes needed to OTC regulation flagged by CHPA's Scott Melville, a sizable eye drops recall, acetaminophen adverse events, and more.
HBW Insight - August 31, 2026
What's happening, why it matters and what's next at FDA. This edition explores the ongoing changes needed to OTC regulation flagged by CHPA's Scott Melville, a sizable eye drops recall, acetaminophen adverse events, and more.
HBW Insight - August 31, 2026
US Rusfertide Approval Fortifies Takeda’s New Product Portfolio
Takeda progresses another key asset in trio of planned near-term launches with US approval of first-in-class polycythemia vera therapy.
Scrip - August 31, 2026
Takeda progresses another key asset in trio of planned near-term launches with US approval of first-in-class polycythemia vera therapy.
Scrip - August 31, 2026
Roche Chases Novartis In Novel ADC Payloads Through DualityBio Deal
Deal Snapshot: Through a deal with DualityBio, Roche follows Novartis into the space of N-myristoyltransferase inhibitors as a novel ADC payload able to overcome resistance to topoisomerase I inhibitors.
Scrip - August 31, 2026
Deal Snapshot: Through a deal with DualityBio, Roche follows Novartis into the space of N-myristoyltransferase inhibitors as a novel ADC payload able to overcome resistance to topoisomerase I inhibitors.
Scrip - August 31, 2026
Executives On The Move: Entera Bio Gets A New CMO As EB613 Heads Into Phase III
Executive changes this week include Entera Bio and Rhythm Pharmaceuticals appointing new CMOs, and Longevica Therapeutics getting a new CEO as the company transitions from drug discovery to drug development.
Scrip - August 31, 2026
Executive changes this week include Entera Bio and Rhythm Pharmaceuticals appointing new CMOs, and Longevica Therapeutics getting a new CEO as the company transitions from drug discovery to drug development.
Scrip - August 31, 2026
Quick Listen: Scrip’s Five Must-Know Things
This week: Lilly study shows Zepbound's cost savings can outweigh its price; Roche's up-to-$2.3bn Hanmi muscle-sparing obesity deal; US approvals for Revolution's Rasonque in pancreatic cancer and Jazz's Ziihera in gastroesophageal cancer; and Teva and Viatris pivot from generics to novelty.
Scrip - August 31, 2026
This week: Lilly study shows Zepbound's cost savings can outweigh its price; Roche's up-to-$2.3bn Hanmi muscle-sparing obesity deal; US approvals for Revolution's Rasonque in pancreatic cancer and Jazz's Ziihera in gastroesophageal cancer; and Teva and Viatris pivot from generics to novelty.
Scrip - August 31, 2026
Rogaine Firm Kenvue’s Challenge Clips Ad Claims For Hims & Hers’ Compounded Hair Growth Drug
Kenvue challenge led National Advertising Division to question Hims & Hers’ use of “trust” as synonymous with “recommend” in claims for hair loss sprays and serums containing minoxidil, the active ingredient also in OTC topicals, and finasteride, available Rx.
HBW Insight - August 31, 2026
Kenvue challenge led National Advertising Division to question Hims & Hers’ use of “trust” as synonymous with “recommend” in claims for hair loss sprays and serums containing minoxidil, the active ingredient also in OTC topicals, and finasteride, available Rx.
HBW Insight - August 31, 2026
Lilly To Pay Up To $2.9bn For Merida Biosciences And Its Antibody-Degrading Autoimmune Platform
Lilly inks its 13th acquisition of 2026 with a deal for Merida Biosciences and its Phase I antibody-degrader.
Scrip - August 31, 2026
Lilly inks its 13th acquisition of 2026 with a deal for Merida Biosciences and its Phase I antibody-degrader.
Scrip - August 31, 2026
Warburg Pincus-Backed Integrace Builds Out Senior Leadership Bench
Integrace, which was acquired by Warburg Pincus in July, assembles senior leadership team to anchor India pharma platform push. Industry veteran Bhaskar Iyer and senior executives from MSD and Roche Diagnostics come on board.
Scrip - August 31, 2026
Integrace, which was acquired by Warburg Pincus in July, assembles senior leadership team to anchor India pharma platform push. Industry veteran Bhaskar Iyer and senior executives from MSD and Roche Diagnostics come on board.
Scrip - August 31, 2026
Pipeline Watch: Eight Approvals And One Phase III Readout
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Scrip - August 31, 2026
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Scrip - August 31, 2026
NSCLC Expansion Win In China Trial For Tagrisso/Orpathys Combo
The clear clinical benefit of the first-line c-Met inhibitor Orpathys and EGFR inhibitor Tagrisso combo could reshape primary treatment strategy for locally advanced or metastatic EGFR-mutated NSCLC with MET overexpression.
Scrip - August 31, 2026
The clear clinical benefit of the first-line c-Met inhibitor Orpathys and EGFR inhibitor Tagrisso combo could reshape primary treatment strategy for locally advanced or metastatic EGFR-mutated NSCLC with MET overexpression.
Scrip - August 31, 2026
ESC: Wainua Data From AstraZeneca/Ionis Undercut ATTR-CM Combo Case
The fine print of a failed trial in transthyretin-mediated amyloid cardiomyopathy muddies the waters on the idea that “silencers” and older “stabilizer” therapies work better together.
Scrip - August 31, 2026
The fine print of a failed trial in transthyretin-mediated amyloid cardiomyopathy muddies the waters on the idea that “silencers” and older “stabilizer” therapies work better together.
Scrip - August 31, 2026
US Rusfertide Approval Fortifies Takeda’s New Product Portfolio
Takeda progresses another key asset in trio of planned near-term launches with US approval of first-in-class polycythemia vera therapy.
Scrip - August 31, 2026
Takeda progresses another key asset in trio of planned near-term launches with US approval of first-in-class polycythemia vera therapy.
Scrip - August 31, 2026
Roche Chases Novartis In Novel ADC Payloads Through DualityBio Deal
Deal Snapshot: Through a deal with DualityBio, Roche follows Novartis into the space of N-myristoyltransferase inhibitors as a novel ADC payload able to overcome resistance to topoisomerase I inhibitors.
Scrip - August 31, 2026
Deal Snapshot: Through a deal with DualityBio, Roche follows Novartis into the space of N-myristoyltransferase inhibitors as a novel ADC payload able to overcome resistance to topoisomerase I inhibitors.
Scrip - August 31, 2026
Executives On The Move: Entera Bio Gets A New CMO As EB613 Heads Into Phase III
Executive changes this week include Entera Bio and Rhythm Pharmaceuticals appointing new CMOs, and Longevica Therapeutics getting a new CEO as the company transitions from drug discovery to drug development.
Scrip - August 31, 2026
Executive changes this week include Entera Bio and Rhythm Pharmaceuticals appointing new CMOs, and Longevica Therapeutics getting a new CEO as the company transitions from drug discovery to drug development.
Scrip - August 31, 2026
Quick Listen: Scrip’s Five Must-Know Things
This week: Lilly study shows Zepbound's cost savings can outweigh its price; Roche's up-to-$2.3bn Hanmi muscle-sparing obesity deal; US approvals for Revolution's Rasonque in pancreatic cancer and Jazz's Ziihera in gastroesophageal cancer; and Teva and Viatris pivot from generics to novelty.
Scrip - August 31, 2026
This week: Lilly study shows Zepbound's cost savings can outweigh its price; Roche's up-to-$2.3bn Hanmi muscle-sparing obesity deal; US approvals for Revolution's Rasonque in pancreatic cancer and Jazz's Ziihera in gastroesophageal cancer; and Teva and Viatris pivot from generics to novelty.
Scrip - August 31, 2026
Boston Scientific Discontinues Imager II Catheter. FDA Issues Early Alert Over Detachment Risk
The FDA said Boston Scientific is removing its Imager II Angiographic Catheters because a manufacturing issue could cause the catheter tip to degrade and detach during use. The company has also decided to discontinue the device. Two serious injuries and no deaths are associated with the recall.
Medtech Insight - August 31, 2026
The FDA said Boston Scientific is removing its Imager II Angiographic Catheters because a manufacturing issue could cause the catheter tip to degrade and detach during use. The company has also decided to discontinue the device. Two serious injuries and no deaths are associated with the recall.
Medtech Insight - August 31, 2026
Philips Joins ARPA-H’s Autonomous Stroke Intervention Race With $33.7m Award
ARPA-H is funding four competing teams to solve the same problem — too few stroke specialists, too far from too many patients — and Philips' $33.7m award is the latest piece of a $175m bet on autonomous endovascular robotics.
Medtech Insight - August 31, 2026
ARPA-H is funding four competing teams to solve the same problem — too few stroke specialists, too far from too many patients — and Philips' $33.7m award is the latest piece of a $175m bet on autonomous endovascular robotics.
Medtech Insight - August 31, 2026
MHRA Directs NHS To Review Cobalt-Chrome Modular-Neck Hip Implants From Five Makers
The UK regulator's review of cobalt-chrome dual-taper modular-neck hip systems from manufacturers like Stryker and Smith+Nephew found heightened wear, corrosion and tissue-reaction risks in about 750 patients. All affected implants had already been withdrawn from the market.
Medtech Insight - August 31, 2026
The UK regulator's review of cobalt-chrome dual-taper modular-neck hip systems from manufacturers like Stryker and Smith+Nephew found heightened wear, corrosion and tissue-reaction risks in about 750 patients. All affected implants had already been withdrawn from the market.
Medtech Insight - August 31, 2026
Herbalife Approaching Executive Suite Shift While Pivoting To Personalization Focus
Nutrition, health and wellness product direct seller says CEO Stephan Gratziani will leave on Oct. 31 while continuing as a strategy and business development consultant and CFO John DeSimone will serve as interim CEO before retiring at the end of the year.
HBW Insight - August 31, 2026
Nutrition, health and wellness product direct seller says CEO Stephan Gratziani will leave on Oct. 31 while continuing as a strategy and business development consultant and CFO John DeSimone will serve as interim CEO before retiring at the end of the year.
HBW Insight - August 31, 2026
Global Regulators Align on Cosmetics E-Labeling
Cosmetic regulators from across the globe came together and agreed on general principles for minimizing barriers to trade at the meeting of the International Cooperation on Cosmetics Regulation this summer.
HBW Insight - August 31, 2026
Cosmetic regulators from across the globe came together and agreed on general principles for minimizing barriers to trade at the meeting of the International Cooperation on Cosmetics Regulation this summer.
HBW Insight - August 31, 2026
FDA Consumer Health Advisory: Further OTC Regulatory Reform Needed
What's happening, why it matters and what's next at FDA. This edition explores the ongoing changes needed to OTC regulation flagged by CHPA's Scott Melville, a sizable eye drops recall, acetaminophen adverse events, and more.
HBW Insight - August 31, 2026
What's happening, why it matters and what's next at FDA. This edition explores the ongoing changes needed to OTC regulation flagged by CHPA's Scott Melville, a sizable eye drops recall, acetaminophen adverse events, and more.
HBW Insight - August 31, 2026
Rogaine Firm Kenvue’s Challenge Clips Ad Claims For Hims & Hers’ Compounded Hair Growth Drug
Kenvue challenge led National Advertising Division to question Hims & Hers’ use of “trust” as synonymous with “recommend” in claims for hair loss sprays and serums containing minoxidil, the active ingredient also in OTC topicals, and finasteride, available Rx.
HBW Insight - August 31, 2026
Kenvue challenge led National Advertising Division to question Hims & Hers’ use of “trust” as synonymous with “recommend” in claims for hair loss sprays and serums containing minoxidil, the active ingredient also in OTC topicals, and finasteride, available Rx.
HBW Insight - August 31, 2026
Apotex Addresses Tariffs As US-Canada Tensions Rise
Following the recent threat of US tariffs on imported generics from 2028, Apotex’s management has spoken about the uncertainty that remains surrounding the measure - but at the same time, says it is aligned with the Trump administration on its underlying goals.
Generics Bulletin - August 28, 2026
Following the recent threat of US tariffs on imported generics from 2028, Apotex’s management has spoken about the uncertainty that remains surrounding the measure - but at the same time, says it is aligned with the Trump administration on its underlying goals.
Generics Bulletin - August 28, 2026
Takeda Patent Suit Puts Early Entyvio Biosimilar Launches Under Pressure
Takeda’s six-patent suit against Polpharma puts an early legal test in front of first-wave Entyvio biosimilar entrants, with both Polpharma and Alvotech targeting potential US approval in 2027.
Generics Bulletin - August 28, 2026
Takeda’s six-patent suit against Polpharma puts an early legal test in front of first-wave Entyvio biosimilar entrants, with both Polpharma and Alvotech targeting potential US approval in 2027.
Generics Bulletin - August 28, 2026
Mylan, Lannett Must Face Humana Jury On Generic Price-Fixing Claims
A US federal court has cleared Humana’s overarching conspiracy and multiple drug-specific claims against Mylan and Lannett for trial, setting up a September bellwether in the generic price-fixing multi-district litigation.
Generics Bulletin - August 28, 2026
A US federal court has cleared Humana’s overarching conspiracy and multiple drug-specific claims against Mylan and Lannett for trial, setting up a September bellwether in the generic price-fixing multi-district litigation.
Generics Bulletin - August 28, 2026
Lupin Targets Bigger Global Role For Europe And Emerging Markets
In an exclusive interview, Lupin’s Thierry Volle describes how the firm is looking to roughly double its Europe and emerging markets business over five years, leaning on specialty care, selective biosimilars and complex generics.
Generics Bulletin - August 28, 2026
In an exclusive interview, Lupin’s Thierry Volle describes how the firm is looking to roughly double its Europe and emerging markets business over five years, leaning on specialty care, selective biosimilars and complex generics.
Generics Bulletin - August 28, 2026
De-Risked Doesn’t Mean It’s A Safe Bet
Big pharma's late-stage M&A is not delivering: across deals since 2021, only 12 of the 33 involving a de-risked asset generated a multiple above 1.0x. In nearly two-thirds of cases the consensus forecast value of the late-stage assets acquired was less than the price paid for the company.
In Vivo - August 29, 2026
Big pharma's late-stage M&A is not delivering: across deals since 2021, only 12 of the 33 involving a de-risked asset generated a multiple above 1.0x. In nearly two-thirds of cases the consensus forecast value of the late-stage assets acquired was less than the price paid for the company.
In Vivo - August 29, 2026